Photoimmunotherapy drugs that target cancer cells
Raised to date
$113.4M
of $118.5M offered across 3 Form D filings
Rakuten Medical, Inc. is a biotechnology company focused on developing advanced cancer treatments through their innovative photoimmunotherapy technology. Their mission is to provide more precise and effective therapeutic options, specifically targeting cancer cells to minimize collateral damage to healthy tissues.
The company's unique approach lies in its use of light-activated drugs combined with targeted antibodies, offering new hope for precision cancer treatment.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Apr 13, 2026 | Equity | $111.5M/ $116.7M | Form D |
| May 7, 2025 | Security to be acquired | $1.9M/ $1.9M | Form D/A |
| Feb 5, 2025 | Security to be acquired | $1.4M/ $1.4M | Form D |
Photoimmunotherapy
ASP-1929 is a pioneering cancer treatment under development that employs Rakuten Medical's photoimmunotherapy technology. This approach uses antibodies that specifically bind to cancer cells and are activated by an external light source, enhancing treatment precision.
Built for
Healthcare providers and medical facilities
